Andrew Gengos Buys 10,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Andrew Gengos bought 10,000 shares of the stock in a transaction dated Friday, June 13th. The shares were bought at an average price of $3.73 per share, for a total transaction of $37,300.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at approximately $37,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Gengos also recently made the following trade(s):

• On Monday, June 16th, Andrew Gengos bought 5,000 shares of Terns Pharmaceuticals stock. The shares were bought at an average price of $3.95 per share, for a total transaction of $19,750.00.

Terns Pharmaceuticals Price Performance

Shares of TERN stock traded up $0.13 during trading on Monday, hitting $4.01. 462,725 shares of the stock traded hands, compared to its average volume of 1,500,307. The firm has a market capitalization of $350.22 million, a P/E ratio of -3.40 and a beta of -0.18. The firm's fifty day moving average price is $3.02 and its 200-day moving average price is $4.01. Terns Pharmaceuticals, Inc. has a 52-week low of $1.87 and a 52-week high of $11.40.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. As a group, equities research analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Institutional Trading of Terns Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in Terns Pharmaceuticals by 21.0% during the first quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company's stock worth $1,145,000 after purchasing an additional 71,971 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Terns Pharmaceuticals during the first quarter worth $51,000. Parkman Healthcare Partners LLC lifted its stake in Terns Pharmaceuticals by 15.8% during the first quarter. Parkman Healthcare Partners LLC now owns 959,703 shares of the company's stock worth $2,649,000 after purchasing an additional 130,598 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Terns Pharmaceuticals during the first quarter worth $1,366,000. Finally, Cubist Systematic Strategies LLC lifted its stake in Terns Pharmaceuticals by 136.8% during the first quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company's stock worth $78,000 after purchasing an additional 16,363 shares in the last quarter. Hedge funds and other institutional investors own 98.26% of the company's stock.

Wall Street Analyst Weigh In

TERN has been the topic of several recent research reports. BMO Capital Markets lowered their target price on Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. JMP Securities restated a "market outperform" rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Finally, William Blair restated a "market perform" rating on shares of Terns Pharmaceuticals in a report on Friday, March 21st. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $15.63.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.